drugset

drugset / Trial / NCT02163902

Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

NCT02163902 ↗

Phase 3 Completed 224 enrolled Kythera Biopharmaceuticals

Non-randomizedParallel-groupDouble-blindOther

Summary

The investigation of the long-term safety and maintenance of efficacy of ATX-101 in reduction of submental fat.

Timeline

Start: 2013-12
Primary completion: 2016-01
Completion: 2016-08

Publications

Humphrey S, Cohen JL, Bhatia AC, Green LJ, Green JB, Bowen B. Improvements in Submental Contour up to 3 Years After ATX-101: Efficacy and Safety Follow-Up of the Phase 3 REFINE Trials. Aesthet Surg J. 2021 Oct 15;41(11):NP1532-NP1539. doi: 10.1093/asj/sjab100.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Deoxycholic Acid	Small molecule	—	—

Indications

No indication recorded.